A drug originally developed to treat Alzheimer's disease may also help teenagers with autism improve their communication skills, according to a new study.The drug, called memantine (sold under the ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...

Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) have completed a successful Phase 1 clinical trial of a novel vaccine designed to ...

The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease returning ...

Cemiplimab (Libtayo; Regeneron Pharmaceuticals) has been approved as an adjuvant treatment for adult patients with cutaneous ...

Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared ...

Tramadol, a potent synthetic opioid, has been widely used to treat moderate to severe pain, but a new study suggests that the ...

Treatments for achondroplasia, acute myeloid leukemia, familial chylomicronemia syndrome, immunoglobulin A nephropathy, and non-small cell lung cancer are under review.

The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...